Microdosing a GLP-1: What Evidence Exists

Microdosing — taking a GLP-1 at doses below the labeled starting dose, usually for maintenance or for gentler side effects — has become a product category. 62 of the 560 sellers we track offer one. The published literature on whether it works consists almost entirely of clinicians writing to journals about what to tell patients who ask for it.

What the literature actually contains

Searching for microdosing, microdose, low-dose, subtherapeutic and dose-reduction maintenance across semaglutide and tirzepatide returns a small, specific body of work. It is not empty. It is also not what most people would expect a product category this size to rest on.

• A 2025 letter in Diabetes Care on understanding microdosing semaglutide in multi-dose pens, and a published comment replying to it.
• A 2026 piece in Obesity considering microdosing tirzepatide in multi-dose pens, and a letter replying to that.
• A 2026 article in a nurse practitioners’ journal whose own title describes the task as balancing patient anecdotes with clinical safety.

That is a conversation among clinicians about how to respond to demand. It is a reasonable and useful conversation. It is not evidence that the practice achieves what it is sold to achieve, and no randomized trial of microdosing was identified under any of those search terms.

Why the idea is plausible anyway

Microdosing is not a fringe notion, and dismissing it would be as unearned as endorsing it. Two reasonable arguments sit behind it.

1. Maintenance may not need the treatment dose. The dose that produces weight loss and the dose that holds it are not obviously the same, and every trial in this class was designed to test the first question rather than the second.
2. Side effects are dose-related. Someone who cannot tolerate the labeled starting dose has a real problem, and a smaller dose is an obvious thing to try before giving up on the drug entirely.

Both are sensible hypotheses, and the first now has partial randomized support from an adjacent question: a 2026 trial that stepped people down to a lower labeled dose found it held much of the loss, while tripling the proportion needing rescue therapy. We cover it in can you lower the dose and keep the weight off. What remains untested is dosing below the labeled range, which is what is being sold.

A plausible idea being sold as a product is not the same as a tested one. The distance between those is where this category currently sits.

What a buyer is actually agreeing to

The commercial framing matters here more than usual, because a microdose plan is typically cheaper, and cheaper is the reason people choose it. That makes it worth being clear about what is being bought.

• An unstudied dose of a compounded product. Compounding is already outside the FDA-reviewed product; a dose below the labeled range is outside the studied range as well. Two departures, not one.
• No way to know if it is working except your weight. With no trial data on expected response, there is no benchmark to compare yourself against.
• A drug whose sellers set the dose. Our article on dosing errors covers what the FDA has reported about doses set outside the labeled schedule.
• Possibly better tolerability, which is real. If side effects are what stopped you, this is a legitimate thing to raise with a prescriber — as a clinical decision, not a subscription tier.